This bill aims to extend the prohibition on drug manufacturers interfering with access to 340B drugs by repealing a specific provision in Minnesota law. The provision being repealed is Minnesota Statutes 2024, section 62J.96, subdivision 3, which states that the section would expire on July 1, 2027.

By removing this expiration clause, the bill ensures that the protections for access to 340B drugs remain in effect indefinitely, thereby strengthening the ongoing support for entities that rely on these drugs for their patients. This legislative change reflects a commitment to maintaining access to affordable medications for vulnerable populations.

Statutes affected:
Introduction: 62J.96